Prudential Financial
LCTX icon

Prudential Financial’s Lineage Cell Therapeutics LCTX Stock Holding History

Prudential Financial’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39K Buy
+29,795
New +$41.2K ﹤0.01% 2446
2025
Q3 		– Sell
-15,700
Closed -$14.2K – 2486
2025
Q2 		$14.2K Sell
15,700
-16,490
-51% -$9.78K ﹤0.01% 2412
2025
Q1 		$14.5K Buy
32,190
+13,200
+70% +$7.74K ﹤0.01% 2274
2024
Q4 		$9.54K Buy
+18,990
New +$13.9K ﹤0.01% 2280
2022
Q2 		– Sell
-10,485
Closed -$16K – 2717
2022
Q1 		$16K Hold
10,485
– – ﹤0.01% 2588
2021
Q4 		$26K Sell
10,485
-815
-7% -$1.91K ﹤0.01% 2611
2021
Q3 		$28K Buy
+11,300
New +$29K ﹤0.01% 2571
2020
Q1 		– Sell
-19,698
Closed -$18K – 2405
2019
Q4 		$18K Buy
19,698
+2,366
+14% +$1.97K ﹤0.01% 2419
2019
Q3 		$17K Hold
17,332
– – ﹤0.01% 2401
2019
Q2 		$19K Hold
17,332
– – ﹤0.01% 2445
2019
Q1 		$23K Buy
17,332
+816
+5% +$1.01K ﹤0.01% 2419
2018
Q4 		$15K Buy
+16,516
New +$25.3K ﹤0.01% 2368

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Prudential Financial's LCTX Position: Q2 2026 in Review

Prudential Financial opened a new position in Lineage Cell Therapeutics (LCTX) in Q2 2026: 29,795 shares worth $39K. The stake represents ﹤0.01% of the portfolio and ranks #2446 among its holdings. This is a return to the name: Prudential Financial previously reported a position in LCTX as recently as Q2 2025.

Prudential Financial first reported a position in LCTX in Q4 2018 and has held it in 12 quarters since. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Prudential Financial held 29,795 shares of Lineage Cell Therapeutics worth $39K as of Q2 2026.
  • Lineage Cell Therapeutics was a new Prudential Financial position in Q2 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of Prudential Financial's portfolio in Q2 2026, its #2446 holding.
  • Prudential Financial first reported a position in Lineage Cell Therapeutics in Q4 2018 and has held it in 12 quarters since.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.